Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Core Viewpoint - Soligenix, Inc. is focused on advancing its late-stage biopharmaceutical pipeline, particularly in the treatment of rare diseases, with significant upcoming milestones and a strategic approach to resource allocation and potential partnerships [2][8]. Recent Accomplishments - The company announced the conclusion of the first Data Monitoring Committee (DMC) meeting for its Phase 3 study of HyBryte™, confirming no safety concerns and an acceptable safety profile consistent with prior studies [2][5]. - Soligenix expanded its Medical Advisory Board in Europe to enhance strategic guidance for the Phase 3 study of HyBryte™ [5]. - The company appointed Tomas J. Philipson, PhD, as a Strategic Advisor to leverage his extensive government relationships [5]. - The FDA granted orphan drug designation to dusquetide for the treatment of Behçet's Disease based on positive Phase 2a results [5]. Financial Results - For the quarter ended September 30, 2025, Soligenix reported no revenue, with a net loss of $2.5 million, or ($0.58) per share, compared to a net loss of $1.7 million, or ($0.78) per share for the same period in 2024 [4][5]. - Research and development expenses increased to $1.6 million from $1.0 million year-over-year, primarily due to costs associated with the Phase 3 CTCL trial [6]. - General and administrative expenses were $1.0 million, slightly up from $0.9 million in the previous year [7]. - The company's cash position was approximately $10.5 million as of September 30, 2025, providing sufficient operating runway through 2026 [2][7].